In the end, Cramer said Walgreen comes out on top 7-5 on his scorecard. He said this is not a market that values complexity or poor execution and CVS unfortunately has both.

Cramer also considered each company's growth strategy. Last year CVS acquired Caremark, a pharmacy benefits manager, and by all accounts that acquisition has not gone well.

Finally, Cramer considered each company's dividend. After comparing the companies' near identical PE ratios, he said Lowe's dividend clearly comes out on top. His final conclusion: buy Lowe's and sell Home Depot.

Next Cramer looked at how much room each company has for growth. Home Depot expects to open 55 new stores, compared to Lowe's 120 expected new stores. Cramer awarded Lowe's an additional point for its expansion prospects.

Tallying up the points, and accounting for some intangibles, like Johnson's great corporate culture and its famed shareholder Warren Buffet, the prize goes to Johnson & Johnson, he said. Pfizer, he said, may look cheap, but it isn't.

Finally, Cramer looked at each company's product pipeline. Here he found Johnson with 7 to 10 new products expected between 2008 and 2010, while Pfizer expects 15-20 new products in their pipeline. He awarded one point to Pfizer on this front.